Arcus Biosciences, Inc.
- RCUS
- NYSE
- Biotechnology
- Cancer Immunotherapy
- HIF-2a Inhibitor
- Anti-TIGIT Antibody
$22.12
Today −3.07%Quote Oct 16, 2026, 08:00 PM UTC
−13.39%over the last month
Max drawdown −17.7%From 1-month high −17.7%3 months −21.5%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$2.78B
Quote Oct 16
Next earnings
Oct 27
Expected, not confirmed
Analyst target
$40.00
+80.8% from here
Floor
$21.90
1.0% below price
Where the price sits
18 analysts
Analyst range, low to high
$23.00$47.00
- Price $22.12
- Resistance $23.24–$23.48
- Consensus $40.00
The price is just above its floor. Analysts' average target sits about 81% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about RCUSPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
Q2 2026 revenue $41.0M
- Other Collaboration Revenue$25.0M61.0%
- License And Development Services$16.0M39.0%
Industry
Biotechnology
Employees
601
Founded
2015